




RealRate

PHARMACEUTICAL 2021

Iterum Therapeutics plc Rank 340 of 409





RealRate

PHARMACEUTICAL 2021

Iterum Therapeutics plc Rank 340 of 409



The relative strengths and weaknesses of Iterum Therapeutics plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Iterum Therapeutics plc compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Iterum Therapeutics plc is the variable Assets, Current, reducing the Economic Capital Ratio by 177% points.

The company's Economic Capital Ratio, given in the ranking table, is -459%, being 105% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	21,472
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	41,698
Liabilities, Non-Current	28,264
Other Assets	10,899
Other Compr. Net Income	0
Other Expenses	743
Other Liabilities	13,389
Other Net Income	-19,137
Property and Equipment	421
Research and Development	21,074
Revenues	0
Selling, General and Administrative Expense	11,052

Output Variable	Value in 1000 USD
Assets	32,792
Liabilities	83,351
Expenses	32,869
Stockholders Equity	-50,559
Net Income	-52,006
Comprehensive Net Income	-52,006
Economic Capital Ratio	-459%



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai